Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250402 | 0.87 | SCN10A (0.41) | CNR2 | |
| SCHEMBL14889668 | 0.83 | CNR2 (0.43) | CNR2 | |
| SCHEMBL3251915 | 0.81 | OPRK1 (0.48) | — | |
| SCHEMBL3247164 | 0.79 | OPRK1 (0.47) | — | |
| SCHEMBL15776061 | 0.78 | CNR2 (0.63) | CNR2 | |
| SCHEMBL14889617 | 0.75 | SMO (0.41) | CNR2 | |
| SCHEMBL28972384 | 0.73 | MAPK1 (0.46) | — | |
| SCHEMBL23612212 | 0.72 | SCN10A (0.41) | CNR2 | |
| SCHEMBL10117524 | 0.71 | PRKCQ (0.39) | — | |
| SCHEMBL2255424 | 0.70 | MAPK1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928882-B1 | PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-2928882-B1 | PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-9512141-B2 | Pyrazine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512141-B2 | Pyrazine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512141-B2 | Pyrazine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2771327-B1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| EP-2771327-B1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| US-9403808-B2 | Pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403808-B2 | Pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403808-B2 | Pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150299220-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2928882-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| EP-2771327-A1 | NOVEL PYRAZINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-03 | — | — | EP | disclosed |
| WO-2014086807-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086807-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| WO-2013060751-A1 | NOVEL PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-02 | — | — | WO | disclosed |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2013060751-A1 | NOVEL PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-02 | — | — | WO | disclosed |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299220-A1 | NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | CNR1, CNR2, GPR55 | CNR2 2/4885CNR1 1/4885 |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | CNR2, CNR1, GPR174 | CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.